FINWIRES · TerminalLIVE
FINWIRES

研究快讯:Payc第一季度业绩超预期,尽管增长放缓,仍向股东返还超过10亿美元

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:PAYC公布了2026年第一季度稳健的业绩,营收达5.72亿美元(同比增长8%),非GAAP每股收益为3.15美元(同比增长13%),超出市场预期0.16美元,调整后EBITDA利润率增至48.2%。9%的经常性营收增长率较以往两位数增速有所放缓,与管理层此前保守的2026年营收增长预期(6%-7%)相符。我们认为,PAYC的人工智能自动化解决方案,包括Beti、GONE和IWant,将使公司成为行业差异化的领导者,从而提升客户参与度和满意度。管理层强调了对长期增长机遇的信心,并指出目前仅覆盖了潜在市场的5%。公司仍保持积极的资本配置策略,回购股票10.6亿美元,派发股息1770万美元,尽管新增债务6.75亿美元,但总回报仍超过10.8亿美元。公司将利用其以员工为先的技术平台,抓住尚未开发的市场机遇,预计运营杠杆和市场份额将持续增长。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661